1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Novartis Poised To Be First To Market With IL-17 Blocker For Psoriasis

 
• By Jessica Merrill

The Swiss drug maker filed its IL-17 inhibitor secukinumab in the U.S. and Europe, providing an opportunity to beat rivals Amgen and Eli Lilly to the market with a first-in-class drug. Secukinumab is one of two drugs Novartis filed in the fourth quarter, the firm reported during a year-end earnings call Jan. 29.

Novartis AG is positioned to beat rivals Amgen Inc./AstraZeneca PLC and Eli Lilly & Co. to market with a first-in-class IL-17 inhibitor for psoriasis. The company said during a year-end sales and earnings call Jan. 29 that it filed its IL-17 blocker secukinumab with regulatory authorities in the U.S. and Europe in the fourth quarter, with action on the applications expected in late-2014.

Novartis is in a tight race with Amgen/AstraZeneca and Lilly to bring an IL-17 blocker to market. The category of drugs has demonstrated notable efficacy in clinical trials, including superiority...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

More from R&D

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Pink Sheet Podcast: US FDA’s Big Vaccine Policy Week

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss the new clinical trial requirements that the FDA announced for COVID-19 vaccines, the updated label for Novavax’s newly approved COVID-19 vaccine, and other vaccine-related events that were part of a busy week for policy in the sector.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.